Search
Interferon beta-1a
go.drugbank.com/drugs/DB00060ApprovedInvestigationalHuman interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced.
Categories: interferon beta-1a, Interferon Type ISynonyms: Interferon beta 1-a, IFN β-1aLanreotide
go.drugbank.com/drugs/DB06791ApprovedInvestigationalIt is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007. … This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsProducts: SOMATULINE ® AUTOGEL ® 60 MG, SOMATULINE AUTOGEL 120 MG/0,5 ML UZATILMIŞ SALIMLI ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ŞIRINGA, 1 ADETDuloxetine
go.drugbank.com/drugs/DB00476ApprovedInvestigationalDuloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. … [L6454] It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence.
Categories: Heterocyclic Compounds, 1-Ring, P-glycoprotein inhibitorsSynonyms: (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine, (S)-duloxetineValdecoxib
go.drugbank.com/drugs/DB00580ApprovedWithdrawnValdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Categories: Heterocyclic Compounds, 1-Ring, COX-2 InhibitorsProducts: BEXTRA ® 10 MG TABLETAS RECUBIERTAS, BEXTRA®20 MG TABLETAS RECUBIERTASSapropterin
go.drugbank.com/drugs/DB00360ApprovedInvestigationaltryptophan to 5-hydroxytryptophan via tryptophan hydroxylase. … It is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa by the enzyme tyrosine hydroxylase; and conversion of
Categories: P-glycoprotein inhibitors, Heterocyclic Compounds, 2-RingSynonyms: 2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydoro-4(1H)-pteridinone, (−)-(6R)-2-amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(3H)-pteridinonePentetic acid
go.drugbank.com/drugs/DB14007ApprovedInvestigational[A32501] It is currently considered, in all the dosage forms, as a member of the list of approved inactive ingredients for drug products by the FDA. … [L2242] DPTA was developed by the pharmaceutical company CIS US and FDA approved on April 14, 2004.[L1469]
Categories: Compounds used in a research, industrial, or household settingSynonyms: DTP-AThiocolchicoside
go.drugbank.com/drugs/DB11582InvestigationalIt is a muscle relaxant with anti-inflammatory and analgesic effects. It has potent convulsant activity and should not be administered to individuals prone to seizures.[L1663] … Thiocolchicoside is a semi-synthetic derivative of the colchicine, a natural anti-inflammatory glycoside which originates from the flower seeds of _Superba gloriosa_.
Mixtures: LEODEX PLUS 50 MG/8 MG FILM KAPLI TABLET,10 TABLET, TIYOKSEN 550 MG/8 MG FILM TABLET,10 ADETSynonyms: Thiocolchicine 2-glucoside analogOmalizumab
go.drugbank.com/drugs/DB00043ApprovedInvestigationalOmalizumab is a recombinant DNA-derived humanized monoclonal antibody directed against human immunoglobulin E (IgE). … [L50482] It is used to treat a range of immune and inflammatory conditions, including allergies, urticaria, and asthma.[A263507]
Products: XOLAIR ® 150 MG, XOLAIR 150 MG/ML ENJEKSIYONLUK COZELTI İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETSatralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigationaloccurs in a pH-dependent manner[A218551] - this allows satralizumab to bind an IL-6 receptor until it reaches an endosome, after which the drug may dissociate from the receptor and move back into the … [A218551] Some of the pro-inflammatory mechanisms involved in NMOSD are thought to be mediated, at least in part, by IL-6, including increased production of anti-aquaporin-4 (AQP4) autoantibodies and increased
Categories: Interleukin-6 Receptor AntagonistSynonyms: Humanised anti-IL-6 receptor monoclonal antibody